CN1969871A - Antivirus compound formulation, preparation process, quality control method and use thereof - Google Patents
Antivirus compound formulation, preparation process, quality control method and use thereof Download PDFInfo
- Publication number
- CN1969871A CN1969871A CN 200510123994 CN200510123994A CN1969871A CN 1969871 A CN1969871 A CN 1969871A CN 200510123994 CN200510123994 CN 200510123994 CN 200510123994 A CN200510123994 A CN 200510123994A CN 1969871 A CN1969871 A CN 1969871A
- Authority
- CN
- China
- Prior art keywords
- total flavones
- herba epimedii
- radix scutellariae
- extract
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 42
- 238000009472 formulation Methods 0.000 title claims description 26
- 230000002155 anti-virotic effect Effects 0.000 title claims description 21
- 238000003908 quality control method Methods 0.000 title claims description 6
- 229930003944 flavone Natural products 0.000 claims abstract description 177
- 235000011949 flavones Nutrition 0.000 claims abstract description 177
- 150000002213 flavones Chemical class 0.000 claims abstract description 148
- 239000007788 liquid Substances 0.000 claims abstract description 50
- 239000007924 injection Substances 0.000 claims abstract description 25
- 238000002347 injection Methods 0.000 claims abstract description 25
- 239000008187 granular material Substances 0.000 claims abstract description 14
- 239000003826 tablet Substances 0.000 claims abstract description 13
- 206010022000 influenza Diseases 0.000 claims abstract description 10
- 239000006187 pill Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000007919 dispersible tablet Substances 0.000 claims abstract description 6
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 5
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims abstract description 3
- 208000006673 asthma Diseases 0.000 claims abstract description 3
- 206010064097 avian influenza Diseases 0.000 claims abstract description 3
- 235000018905 epimedium Nutrition 0.000 claims abstract description 3
- 230000036039 immunity Effects 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 215
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 82
- 239000000706 filtrate Substances 0.000 claims description 62
- 239000000284 extract Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 39
- 239000000047 product Substances 0.000 claims description 27
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 23
- 229930195725 Mannitol Natural products 0.000 claims description 23
- 239000000594 mannitol Substances 0.000 claims description 23
- 235000010355 mannitol Nutrition 0.000 claims description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 239000012141 concentrate Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 18
- 239000007937 lozenge Substances 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 15
- IYCPMVXIUPYNHI-WPKKLUCLSA-N 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-WPKKLUCLSA-N 0.000 claims description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 12
- FXNFHKRTJBSTCS-UHFFFAOYSA-N baicalein Chemical compound C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 12
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 238000007639 printing Methods 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 230000000840 anti-viral effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000006196 drop Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 238000011067 equilibration Methods 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 230000008023 solidification Effects 0.000 claims description 8
- 238000007711 solidification Methods 0.000 claims description 8
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 6
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 claims description 6
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 6
- 229960003321 baicalin Drugs 0.000 claims description 6
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 235000015838 chrysin Nutrition 0.000 claims description 6
- 229940043370 chrysin Drugs 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 229930182470 glycoside Natural products 0.000 claims description 6
- 150000002338 glycosides Chemical class 0.000 claims description 6
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 6
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 6
- 210000000214 mouth Anatomy 0.000 claims description 6
- 229960001285 quercetin Drugs 0.000 claims description 6
- 235000005875 quercetin Nutrition 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 238000010998 test method Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000005496 eutectics Effects 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 4
- 150000004729 acetoacetic acid derivatives Chemical class 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000012869 ethanol precipitation Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 238000000859 sublimation Methods 0.000 claims description 4
- 230000008022 sublimation Effects 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 241000893536 Epimedium Species 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000001647 drug administration Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000013599 spices Nutrition 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 29
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 29
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 29
- 241001016310 Epimedium grandiflorum Species 0.000 abstract 1
- 208000002979 Influenza in Birds Diseases 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 239000006190 sub-lingual tablet Substances 0.000 abstract 1
- 230000006837 decompression Effects 0.000 description 38
- 238000004064 recycling Methods 0.000 description 38
- 238000010992 reflux Methods 0.000 description 28
- 239000003480 eluent Substances 0.000 description 27
- 238000001291 vacuum drying Methods 0.000 description 25
- 235000008504 concentrate Nutrition 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 238000010828 elution Methods 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 239000000945 filler Substances 0.000 description 12
- 238000003795 desorption Methods 0.000 description 11
- 238000011010 flushing procedure Methods 0.000 description 11
- 206010016825 Flushing Diseases 0.000 description 10
- 239000004952 Polyamide Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229920002647 polyamide Polymers 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000012216 screening Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- -1 filters Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000003350 kerosene Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- IOHZJWGBFQYXRW-GTDRIFFSSA-M sodium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol chloride Chemical compound [Na+].[Cl-].O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O IOHZJWGBFQYXRW-GTDRIFFSSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a compound preparation comprising scutellaria root flavones and barren wort flavone, and can be prepared into injections, capsules, tablets, dispersible tablets, sublingual tablets, granules, oral liquid preparations, drop pills and other pharmacologically allowable dose forms. The invention can be applied to the treatment of pneumonia, respiratory tract infection, influenza, avian Influenza, SARS, asthma, and for improving human body immunity.
Description
Technical field
The present invention is a kind of antivirus compound formulation and preparation method thereof, quality control method and application, belongs to technical field of medicaments.
Technical background
Flu is the upper respiratory tract infection that is caused by multiple virus, is commonly called as " cold ", is all generable common respiratory tract diseases of the four seasons.Viral influenza is a upper respiratory tract infection, is called for short again and goes up sense, and be the common respiratory infectious disease that causes by multiple virus.Though it is a lot of to be used for the treatment of the medicine of flu on the market, but the problem that the side effect of Western medicine ubiquity is big, and Chinese patent medicine is according to the different causes of disease, in conjunction with the medicine of theory of Chinese medical science in order to the treatment disease, for example anemofrigid cold, anemopyretic cold etc. all are to need to select different medicines to treat.And at present Western medicine class coldrex exists dizzy, drowsiness, myasthenia of limbs etc. allow the not drawback of fast response of people on the market; And pure Chinese medicine coldrex exists onset to wait shortcoming slowly.Better prevent and treat purpose in order to reach, a large amount of research has been done by many inventors and medicine enterprise, and some outstanding treatment products also are provided; As: number of patent application is: 200410048399.7, name is called the patent application of " a kind of antiviral oral cavity disintegration tablet and preparation method thereof ", and the disease that it is used for the flu aspect has rapid-action effect; But in further investigation, find, adopt the many big prescriptions of flavour of a drug, the complicated component of its preparation, and make patient's dosage big, the applicant has adopted the effective site compatibility of Radix Scutellariae, Herba Epimedii can not only reduce patient's dose on this basis, removes the strong composition of some toxic and side effects in the medicinal substances extract, has improved the safety of preparation and the controllability of quality, greatly improve curative effect, and more help the molding of preparation.
Summary of the invention: the objective of the invention is to: a kind of antiviral Chinese medicine preparation and its production and application is provided; The present invention is directed to prior art, under Chinese medical theory instructs, on the basis of experiment screening, adopt Radix Scutellariae total flavones, Herba Epimedii total flavones compatibility to make preparation, optimize best prescription and technology; The product that obtains, particularly ejection preparation and sublingual lozenge formulation products can play the effect of the first pass effect that absorption is fast, bioavailability is high, rapid-action, avoid liver.
The present invention constitutes like this: calculate according to percentage by weight, it is to be made by Radix Scutellariae total flavones 1～99% and Herba Epimedii total flavones 99～1% and suitable adjuvant.Be preferably: calculate according to percentage by weight, it is to be made by Radix Scutellariae total flavones 20～80% and Herba Epimedii total flavones 80～20% and suitable adjuvant.
Say accurately: calculate according to percentage by weight, it is to be made by Radix Scutellariae total flavones 60～40%, Herba Epimedii total flavones 40～60% and suitable adjuvant.
The preparation method of described antivirus compound formulation: Radix Scutellariae total flavones can be the highly finished product of Radix Scutellariae alcohol extract, Radix Scutellariae water extract, Radix Scutellariae water extract-alcohol precipitation extract, Radix Scutellariae semi-bionic extraction thing, Radix Scutellariae supercritical extract or above each extract; Herba Epimedii total flavones can be the highly finished product of Herba Epimedii alcohol extract, Herba Epimedii water extract, Herba Epimedii water extract-alcohol precipitation extract, Herba Epimedii semi-bionic extraction thing, Herba Epimedii supercritical extract or above each extract.
Described preparation can be any acceptable dosage form on the pharmaceutics: the injection that is directly used in drug administration by injection, directly supply the venous transfusion of intravenous drip, need to be used for the concentrated solution for injection of intravenous drip and injectable sterile powder and aseptic block and the tablet that makes with freeze-drying or spray drying method after the dilution, capsule, granule, drop pill, pill, soft capsule, oral liquid, all receptible dosage forms on the pharmaceutics such as oral cavity disintegration tablet or dispersible tablet.Say accurately: described preparation can be various injections, drop pill, sublingual lozenge, oral cavity disintegration tablet, dispersible tablet, soft capsule, capsule, ordinary tablet.
Described preparation can make on the basis that in Radix Scutellariae total flavones, the Herba Epimedii total flavones one or both is prepared into liposome or pro-liposome.
Contain flavones ingredient in the described preparation, wherein 70% of the total solid of the total flavones in the injection after greater than deduction adjuvant amount and water quantities in the preparation, the total solid of the total flavones in the oral formulations after greater than deduction adjuvant amount and water quantities in the preparation 50% ".
Described drug effective region is commercially available or adopts following method to prepare:
A, Radix Scutellariae total flavones effective site are preparations like this: get radix scutellariae medicinal materials, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Scutellariae total flavones crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Scutellariae total flavones effective site;
B, Herba Epimedii total flavones effective site are preparations like this: get epimedium herb, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Herba Epimedii total flavones crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Herba Epimedii total flavones effective site.
Injectable sterile block in the described preparation prepares like this: get Radix Scutellariae total flavones, Herba Epimedii total flavones, add 1800ml water for injection, press medicine and added mannitol than 1: 2.2 with supplementary product consumption, with saturated sodium hydroxide solution adjust pH to 6.5～7.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.4% boiled coarse filtration 40 minutes, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, equilibration time when the balance solidification point of phase I is 0 ℃ is 3.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-35 ℃, needs 3.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-40 ℃ of constant temperature slowly heats up 3～5 ℃/h, to the lowest total of the melting point temperature, the time is about 8 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 4～6 hours, kept more than 35 ℃ dry 4 hours, gland, promptly.
Described sublingual lozenge is such preparation: the extract of getting Radix Scutellariae total flavones, Herba Epimedii total flavones mixes, and adds 5% lactose, 15% mannitol, 25% magnesium stearate, crosses 30 mesh sieves, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets sublingual lozenge.The adjuvant of sublingual lozenge can be following one or more: lactose, mannitol, corn starch, polyvinylpyrrolidone K30, citric acid, sodium citrate, magnesium stearate, xanthein, acetoacetate derivative, sweeting agent, lemon flavouring.
Described pharmaceutical adjunct can be one or more in lactose, galactose, mannitol, corn starch, polyvinylpyrrolidone K30, citric acid, sodium citrate, magnesium stearate, pigment, acetoacetate derivative, sweeting agent, spice, glycine, glucose, sodium chloride, dextran, glycerol, ethanol, propylene glycol, Polyethylene Glycol, sorbitol, tween, HP-, the poloxamer.
Pro-liposome in the described preparation prepares like this: get Radix Scutellariae total flavones, Herba Epimedii total flavones, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir supersound process, freezing, the dry powder that obtains sieves, promptly.
Described method of quality control comprise in the following method partly or entirely:
(1) finger printing of anti-viral pharmaceutical compositions test comprises based on the finger printing of Radix Scutellariae total flavones composition characteristics with based in the finger printing of Herba Epimedii total flavones composition characteristics one or more;
(2) baicalin, noroxylin, chrysin, icariin, icariside I, Herba Epimedii glycosides A, B, C, precious icariin I, II, the differential test method of all or part of composition in VI, the Quercetin;
(3) baicalin, noroxylin, chrysin, icariin, icariside I, Herba Epimedii glycosides A, B, C, precious icariin I, II, the content test method of all or part of composition in VI, Quercetin, the total flavones.
Described preparation is used to prepare the medicine of diseases such as treatment pneumonia, respiratory tract infection, influenza, bird flu, SARS, asthma, human body immunity improving power.
For proving that medicine provided by the invention has effective effect, the applicant has carried out a series of experiments;
Experimental example 1: to the comparative study of different proportioning pharmacodynamics
By the experiment of Diplococcus pneumoniae infecting mouse protective effect, the prescription of different proportion has been carried out the screening test of system, wherein: get 18～22gKM kind mice random packet, 21 every group, 1. the male and female dual-purpose fills a prescription 1: blank group equivalent normal saline; 2. fill a prescription 2: model control group, equivalent normal saline; 3. fill a prescription 3: Radix Scutellariae total flavones/Herba Epimedii total flavones=99/1; 4. fill a prescription 4: Radix Scutellariae total flavones/Herba Epimedii total flavones=80/20; 5. fill a prescription 5: Radix Scutellariae total flavones/Herba Epimedii total flavones=40/60; 6. fill a prescription 6: Radix Scutellariae total flavones/Herba Epimedii total flavones=60/40; 7. fill a prescription 7: Radix Scutellariae total flavones/Herba Epimedii total flavones=20/80; 8. fill a prescription 8: Radix Scutellariae total flavones/Herba Epimedii total flavones=1/99.Each organizes mice by administration in 1 time/day * 6 days, and administration in the 3rd day is after 1 hour, and 0.5ml/ Mus of lumbar injection Diplococcus pneumoniae bacterium liquid (except that the blank group) continues administration 3 days, observes death condition in each treated animal 7 days.The results are shown in Table 1:
Table 1 prescription research conclusion
| Formula number | Number of animals (only) | Death toll (only) | Survival rate (%) |
| 1 2 3 4 5 6 7 8 | 21 21 21 21 21 21 21 21 | 0 18 16 15 12 10 8 16 | 100 14.3 23.8 28.6 57.1 47.6 38.1 23.8 |
By experimental result as can be known, Radix Scutellariae total flavones: best compatibility scope=40～60%: 60～40% of Herba Epimedii total flavones.
Experimental example 2: Study on Forming
2.1 the selection of injection filler kind and consumption
The applicant finds that in development suitable filler, filler loading are powder injection formulation molding and stable key factor, and in order to improve the quality of this powder injection formulation, at first, the applicant investigates the kind of filler.The results are shown in following table.
2.1.1 different filler kind screenings
The different filler lyophilizing of table 2 effect relatively
| Filler | Mannitol | Glucose | Lactose | Sodium chloride | HP-β-CD |
| Medicine: adjuvant mouldability | 1: 2 good | Not molding in 1: 2 | Not molding in 1: 2 | Not molding in 1: 2 | Not molding in 1: 2 |
As seen, because the eutectic point height of mannitol, good water solubility be beneficial to the lyophilizing and the molding of this product, and other filler all is not suitable for this product, so selection mannitol is filler.
2.1.2 the screening of mannitol consumption
The applicant investigates the weight ratio of mannitol and effective ingredient then, the results are shown in following table.
The different filler proportionings of table 3 are to the influence of lyophilizing effect
| Medicine: mannitol | Color | Mouldability | Water solublity | Clarity |
| 1∶1 1∶1.6 1∶2.2 1∶2.9 1∶3.6 | Yellow faint yellow yellowish white | The difference difference is good carefully | The difference difference is good carefully | Difference difference good job is poor |
As seen, medicine: mannitol=1: 2.2 o'clock, formed product is effective, considers from economic angle, determines medicine: mannitol=1: 2.2.
2.2 the selection of sublingual lozenge filler kind and consumption
2.2.1 different filler kind screenings
Sublingual lozenge then is directly to be absorbed and the tablet medicine of performance general action by the Sublingual mucosa.Sublingual lozenge can prevent that gastrointestinal tract from destroying the active ingredient of medicine, also can avoid the drug influence liver function.It is poor to have solved former dosage form disintegrative, and stripping is shortcoming slowly.
Investigation factor and level: pass through preliminary experiment, the rapid release absorption and the curative effect of the viral prescription of antagonism are had the clearly factor of influence: lactose powder (A) mannitol (B) and magnesium stearate (C) and consumption are investigated as variable factor, and each factor is fetched water to put down and seen the following form.Select L9 (4 for use
3) orthogonal table experimentizes.
Table 4 orthogonal test factor level table
| Lactose | Mannitol | Magnesium stearate | |
| 1 2 3 | 20％ 10％ 5％ | 15％ 25％ 35％ | 5％ 15％ 25％ |
With to the survival rate of infection of staphylococcus aureus mice as index, concrete experiment is: get 18～22g, KM kind mice random packet, every group 21, the male and female dual-purpose, each organized administration 1 time/day * 6 days, administration was after 1 hour in the 3rd day, 0.5ml/ Mus of lumbar injection staphylococcus aureus bacterium liquid continued administration 3 days, observed death condition in each treated animal 7 days.Experiment is divided into groups and be the results are shown in following table
Arrangement of table 5 orthogonal test and result
| The factor group number | Lactose | Mannitol | Magnesium stearate | Survival rate (%) |
| 1 2 3 4 5 6 7 8 9 | 1 1 1 2 2 2 3 3 3 | 1 2 3 1 2 3 1 2 3 | 1 2 3 2 3 1 3 1 2 | 19.0 33.3 28.6 23.8 14.3 19.0 38.1 14.3 28.6 |
As seen, adjuvant is selected 5% lactose, 15% mannitol, 25% magnesium stearate, product good drug efficacy for use.
Experimental example 3: preparation pharmacodynamic experiment
3.1 vivo bacteria corrosion action
Protective effect to the infection of staphylococcus aureus mice: get 18～22g, KM kind mice random packet, 21 every group, male and female dual-purpose, 1. blank group equivalent normal saline; 2. model control group, the equivalent normal saline; 3. antiviral granule 3g/kg; 4. injection group 3g/kg of the present invention; 5. sublingual lozenge group 3g/kg of the present invention.Below respectively organize administration 1 time/day * 6 days, administration in the 3rd day is after 1 hour, and 0.5ml/ Mus of lumbar injection staphylococcus aureus bacterium liquid (except that the blank group) continues administration 3 days, observes death condition in each treated animal 7 days, the results are shown in Table.
Table 6 anti-virus formulation is to the protective effect of infection of staphylococcus aureus mice
| Group | Dosage (g/kg) | Number of animals (only) | Death toll (only) | Survival rate (%) |
| Blank group model matched group antiviral granule injection group of the present invention sublingual lozenge group of the present invention | - - 3.00 3.00 3.00 | 21 21 21 21 21 | 0 20 14 10 11 | 100 4.8 33.3 52.4 47.6 |
By experimental result as can be known, than the antiviral granule height, pharmaceutical preparation of the present invention has inhibitory action to staphylococcus aureus to the survival rate of infection of staphylococcus aureus mice in pharmaceutical preparation of the present invention.
3.2 interior resisting virus experiment
The interior resisting virus effect: virus infected mice median lethal dose(LD 50) (LD50) is measured and is got 49 of KM kind mices, body weight 11～13g, the male and female dual-purpose is divided into 7 groups at random, every group 7, get and increase 3 times viral allantoic fluid of poison, with 10 times of dilutions, every group drips a virus concentration, each organize mice under the ether light anaesthesia with viral allantoic fluid 30ul collunarium, observe death toll in 14 days, press Reed Muench method and calculate, LD50 is 2.88.
Protective effect to the influenza a virus infection mice: get KM kind mice, body weight 11～13g, male and female half and half are divided in groups 21 every group (1) blank groups, equivalent normal saline at random; (2) model control group, the equivalent normal saline; (3) ribavirin group 75mg/kg; (4) injection group 3g/kg of the present invention; (5) sublingual lozenge group 3g/kg of the present invention.Below respectively organize mice administration 1 time/* 6 days; in administration respectively organized in the day mice (except that the blank group) under the ether light anaesthesia to increase the viral allantois drop nose infecting mouse of poison 3 times; every Mus 30ul (20 LD50 challenging doses) observes zoogenetic infection sequela symptom; record infects death toll after 14 days; and calculate protective rate and average survival natural law, the results are shown in Table
Table 7 anti-virus formulation is to the protective effect of influenza a virus infection mice
| Group | Dosage (g/kg) | Number of animals (only) | Death toll (only) | Survival rate (%) |
| Blank group model matched group ribavirin group injection group of the present invention sublingual lozenge group of the present invention | - - 0.75 3.00 3.00 | 21 21 21 21 21 | 0 21 7 8 9 | 100 0.0 66.7 61.9 57.1 |
By experimental result as can be known, pharmaceutical preparation of the present invention has obvious protective effect to the influenza a virus infection mice, and pharmaceutical preparation of the present invention has inhibitory action better to influenza A virus.
Concrete embodiment
Embodiments of the invention 1: Radix Scutellariae total flavones 50g Herba Epimedii total flavones 50g
Get Radix Scutellariae total flavones, Herba Epimedii total flavones, add 1800ml water for injection, press medicine and added mannitol than 1: 2.2 with supplementary product consumption, with saturated sodium hydroxide solution adjust pH to 6.5～7.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.4% boiled coarse filtration 40 minutes, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, equilibration time when the balance solidification point of phase I is 0 ℃ is 3.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-35 ℃, needs 3.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-40 ℃ of constant temperature slowly heats up 3～5 ℃/h, to the lowest total of the melting point temperature, the time is about 8 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 4～6 hours, kept more than 35 ℃ dry 4 hours, gland promptly gets the Injectable sterile block.One time 2,1 time on the one, with using behind the 250ml0.9% physiological saline solution.Total flavones wherein accounts for about 55% of total solid
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, add 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filter, filtrate is crossed the AB-8 macroporous resin column, earlier with 6 times of water flushings, reuse 60% alcohol desorption, collect stripping liquid, decompression recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, vacuum drying gets Radix Scutellariae extract.(about general flavone content 55%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed polyamide column, earlier with 8 times of volume water washings, discard eluent, 8 times of volume 70% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 55%)
Embodiments of the invention 2: Radix Scutellariae total flavones 50g Herba Epimedii total flavones 50g
Get Radix Scutellariae total flavones, Herba Epimedii total flavones mixing, add 5% lactose, 15% mannitol, 25% magnesium stearate, cross 30 mesh sieves, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets sublingual lozenge.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, add 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filter, filtrate is crossed the AB-8 macroporous resin column, earlier with 6 times of water flushings, reuse 60% alcohol desorption, collect stripping liquid, decompression recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, vacuum drying gets Radix Scutellariae extract.(about general flavone content 55%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed polyamide column, earlier with 8 times of volume water washings, discard eluent, 8 times of volume 70% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 55%)
Embodiments of the invention 3: Radix Scutellariae total flavones 40g Herba Epimedii total flavones 60g
Get Radix Scutellariae total flavones, Herba Epimedii total flavones, add 1800ml water for injection, press medicine and added mannitol than 1: 2.2 with supplementary product consumption, with saturated sodium hydroxide solution adjust pH to 6.5～7.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.4% boiled coarse filtration 40 minutes, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, equilibration time when the balance solidification point of phase I is 0 ℃ is 3.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-35 ℃, needs 3.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-40 ℃ of constant temperature slowly heats up 3～5 ℃/h, to the lowest total of the melting point temperature, the time is about 8 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 4～6 hours, kept more than 35 ℃ dry 4 hours, gland promptly gets the Injectable sterile block.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, add 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filter, filtrate is crossed the AB-8 macroporous resin column, earlier with 6 times of water flushings, reuse 60% alcohol desorption, collect stripping liquid, decompression recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, vacuum drying gets Radix Scutellariae extract.(about general flavone content 55%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed polyamide column, earlier with 8 times of volume water washings, discard eluent, 8 times of volume 70% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 55%)
Embodiments of the invention 4: Radix Scutellariae total flavones 30g Herba Epimedii total flavones 70g
Get Radix Scutellariae total flavones, Herba Epimedii total flavones mixing, in adding lactose, mannitol, corn starch, polyvinylpyrrolidone K30, citric acid, sodium citrate, magnesium stearate, xanthein, acetoacetate derivative, sweeting agent, the lemon flavouring one or more, cross 30 mesh sieves, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets sublingual lozenge.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, add 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filter, filtrate is crossed the AB-8 macroporous resin column, earlier with 6 times of water flushings, reuse 60% alcohol desorption, collect stripping liquid, decompression recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, vacuum drying gets Radix Scutellariae extract.(about general flavone content 55%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed polyamide column, earlier with 8 times of volume water washings, discard eluent, 8 times of volume 70% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 55%)
Embodiments of the invention 5: Radix Scutellariae total flavones 60g Herba Epimedii total flavones 40g
Above medicament mixed is even, the dextrin of adding equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, and adds 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid, filters decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filters, filtrate stirs with hydrochloric acid adjust pH to 2, and placement is spent the night, filter, precipitation washes with water, drains, and drying under reduced pressure gets Radix Scutellariae extract.(about general flavone content 30%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed polyamide column, earlier with 8 times of volume water and 5 times of volume 10% washing with alcohol, discard eluent, 8 times of volume 60% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 75%)
Embodiments of the invention 6: Radix Scutellariae total flavones 70g Herba Epimedii total flavones 30g
Above medicament mixed is even, add distilled water, filter repeatedly, till the filtrate clarification., filter with absorbent cotton after the stirring and dissolving in filtrate with sucrose, it is an amount of to add distilled water on filter, shakes up, and promptly gets syrup.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, add 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filter, filtrate is crossed the AB-8 macroporous resin column, earlier with 6 times of water and 5 times of 15% alcohol flushing, discards eluent; Reuse 60% alcohol desorption is collected stripping liquid, decompression recycling ethanol, and measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, vacuum drying gets Radix Scutellariae extract.(about general flavone content 75%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed the D-101 macroporous resin column, earlier with 8 times of volume water and 5 times of volume 25% washing with alcohol, discard eluent, 6 times of volume 50% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 85%)
Embodiments of the invention 7: Radix Scutellariae total flavones 20g Herba Epimedii total flavones 80g
Above medicament mixed is even, and in principal agent: the ratio of adjuvant=1.5: 1 adds calcium phosphate, by principal agent: the ratio adding micropowder cellulose of adjuvant=1.0: 1, and press principal agent: the crospolyvinylpyrrolidone of adjuvant=2.5: 1, evenly mixed, make soft material in right amount with 70% ethanol, cross 30 mesh sieve system granules, 60 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets dispersible tablet.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, and adds 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid, filters decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filters, filtrate stirs with hydrochloric acid adjust pH to 2, and placement is spent the night, filter, precipitation washes with water, drains, and drying under reduced pressure gets Radix Scutellariae extract.(about general flavone content 30%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid, filters, and measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, add 4 times of volume water stirring and dissolving, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 30%)
Embodiments of the invention 8: Radix Scutellariae total flavones 25g Herba Epimedii total flavones 75g
Above medicament mixed is even, will be that 1.8: 1 sodium stearate is put in the rustless steel container with the principal agent ratio, add extract, mix homogeneously is heated to 80-85 ℃, treat whole fusions after, 70-75 ℃ of insulation, mechanical high-speed are stirred 15min to evenly, are transferred in the reservoir, the dropping liquid valve is regulated in 70～75 ℃ of insulations, splashes in 30～35 ℃ the kerosene, drip apart from 5～6cm, drip 40～45 droplets/minute of speed, to the greatest extent and wipe kerosene the drop pill drop that forms, packing promptly gets drop pill.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, add 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filter, filtrate is crossed the AB-8 macroporous resin column, earlier with 6 times of water flushings, reuse 60% alcohol desorption, collect stripping liquid, decompression recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, vacuum drying gets Radix Scutellariae extract.(about general flavone content 55%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed polyamide column, earlier with 8 times of volume water and 5 times of volume 10% washing with alcohol, discard eluent, 8 times of volume 60% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 75%)
Embodiments of the invention 9: Radix Scutellariae total flavones 80g Herba Epimedii total flavones 20g
Above medicament mixed is even, add 2.5 times of amount dextrin, 0.4% stevioside, 1.5% microcrystalline Cellulose with an amount of alcoholic solution system soft material, is granulated, and 65 ℃ of forced air dryings are granulated, and granulate promptly gets granule.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, and adds 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid, filters decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filters, filtrate stirs with hydrochloric acid adjust pH to 2, and placement is spent the night, filter, precipitation washes with water, drains, and drying under reduced pressure gets Radix Scutellariae extract.(about general flavone content 30%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed the D-101 macroporous resin column, earlier with 8 times of volume water and 5 times of volume 25% washing with alcohol, discard eluent, 6 times of volume 50% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 85%)
Embodiments of the invention 10: 75 parts of Herba Epimedii total flavones 25g of Radix Scutellariae total flavones
Get the low-substituted hydroxypropyl cellulose and 1.5% sorbitol of above medicine adding 5%, compacting promptly gets oral cavity disintegration tablet in flakes.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, add 8 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, decompression filtrate recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, adds 3 times of volume water dissolutioies, filter, filtrate is crossed the AB-8 macroporous resin column, earlier with 6 times of water flushings, reuse 60% alcohol desorption, collect stripping liquid, decompression recycling ethanol, measuring relative density when being concentrated into 60 ℃ is 1.05～1.15, vacuum drying gets Radix Scutellariae extract.(about general flavone content 55%)
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, add 10 times of volume 70% alcohol reflux 3 times, each 1 hour, merge extractive liquid,, filter, measuring relative density when filtrate is condensed into 50 ℃ is 1.05～1.15, adds 3 times of water gagings, stirring and dissolving, filter, filtrate is crossed the D-101 macroporous resin column, earlier with 8 times of volume water and 5 times of volume 25% washing with alcohol, discard eluent, 6 times of volume 50% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, measuring relative density when being condensed into 50 ℃ is 1.10～1.20, and vacuum drying gets Herba Epimedii extract.(about general flavone content 85%)
Embodiments of the invention 11: Radix Scutellariae total flavones 99g Herba Epimedii total flavones 1g
Above medicine is added suitable adjuvant, evenly mixed, make soft material in right amount with 70% ethanol, cross 20 mesh sieve system granules, 60 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of Pulvis Talci, micropowder silica gel, and evenly mixed, tabletting promptly gets tablet.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, and adds 5 times of volume 30% alcohol reflux 1 time, each 0.1 hour, merge extractive liquid, filters decompression filtrate recycling ethanol, concentrate, add 1 times of volume water dissolution, filter, filtrate is crossed macroporous resin column, earlier with 3 times of water flushings, reuse 30% alcohol desorption, collect stripping liquid, decompression recycling ethanol concentrates, and vacuum drying gets Radix Scutellariae total flavones; (about general flavone content 55%);
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, adds 2 times of volume 20% alcohol reflux 1 time, each 0.1 hour, merge extractive liquid, filters, and filtrate concentrates, add 1 times of water gaging, stirring and dissolving filters, filtrate is crossed polyamide column, earlier with 1 times of volume water washing, discards eluent, 1 times of volume 30% ethanol elution of reuse is collected eluent, decompression recycling ethanol, concentrate, vacuum drying gets Herba Epimedii total flavones; (about general flavone content 55%)
Embodiments of the invention 12: Radix Scutellariae total flavones 90g Herba Epimedii total flavones 10g
Above medicament mixed is even, add 2 times of amount dextrin, 0.5% stevioside, 1.2% microcrystalline Cellulose with an amount of alcoholic solution system soft material, is granulated, and 60 ℃ of forced air dryings are granulated, and granulate promptly gets granule.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, and adds 5 times of volume 30% alcohol reflux 1 time, each 0.1 hour, merge extractive liquid, filters decompression filtrate recycling ethanol, concentrate, add 1 times of volume water dissolution, filter, filtrate is crossed macroporous resin column, earlier with 3 times of water flushings, reuse 30% alcohol desorption, collect stripping liquid, decompression recycling ethanol concentrates, and vacuum drying gets Radix Scutellariae total flavones; (about general flavone content 55%);
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, adds 2 times of volume 20% alcohol reflux 1 time, each 0.1 hour, merge extractive liquid, filters, and filtrate concentrates, add 1 times of water gaging, stirring and dissolving filters, filtrate is crossed polyamide column, earlier with 1 times of volume water washing, discards eluent, 1 times of volume 30% ethanol elution of reuse is collected eluent, decompression recycling ethanol, concentrate, vacuum drying gets Herba Epimedii total flavones; (about general flavone content 55%)
Embodiments of the invention 13: Radix Scutellariae total flavones 1g Herba Epimedii total flavones 99g
Above medicament mixed is even, the dextrin of adding equivalent, mix homogeneously is granulated, and is encapsulated, promptly gets capsule.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, and adds 10 times of volume 90% alcohol reflux 7 times, each 5 hours, merge extractive liquid, filters decompression filtrate recycling ethanol, concentrate, add 6 times of volume water dissolutioies, filter, filtrate is crossed macroporous resin column, earlier with 8 times of water flushings, reuse 90% alcohol desorption, collect stripping liquid, decompression recycling ethanol concentrates, and vacuum drying gets Radix Scutellariae total flavones; (about general flavone content 55%);
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, adds 16 times of volume 90% alcohol reflux 8 times, each 5 hours, merge extractive liquid, filters, and filtrate concentrates, add 8 times of water gagings, stirring and dissolving filters, filtrate is crossed polyamide column, earlier with 12 times of volume water washings, discards eluent, 12 times of volume 90% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, concentrate, vacuum drying gets Herba Epimedii total flavones; (about general flavone content 55%)
Embodiments of the invention 14: Radix Scutellariae total flavones 10g Herba Epimedii total flavones 90g
Above medicament mixed is even, be dissolved in the phosphate buffer (0.15M) standby, a certain proportion of fabaceous lecithin, cholesterol are dissolved in the 18-amine. solution, add in the phosphate-buffered liquor of said medicine, the water-bath type Ultrasound Instrument is handled 10min, gets liposome turbid liquor, behind the frozen drying, cross 180 mesh sieves, aseptic subpackaged, promptly get the pro-liposome injectable powder.
Wherein Radix Scutellariae total flavones can prepare with the following method: Radix Scutellariae is pulverized, and adds 10 times of volume 90% alcohol reflux 7 times, each 5 hours, merge extractive liquid, filters decompression filtrate recycling ethanol, concentrate, add 6 times of volume water dissolutioies, filter, filtrate is crossed macroporous resin column, earlier with 8 times of water flushings, reuse 90% alcohol desorption, collect stripping liquid, decompression recycling ethanol concentrates, and vacuum drying gets Radix Scutellariae total flavones; (about general flavone content 55%);
Wherein Herba Epimedii total flavones can prepare with the following method: Herba Epimedii is cut into 1cm left and right sides segment, adds 16 times of volume 90% alcohol reflux 8 times, each 5 hours, merge extractive liquid, filters, and filtrate concentrates, add 8 times of water gagings, stirring and dissolving filters, filtrate is crossed polyamide column, earlier with 12 times of volume water washings, discards eluent, 12 times of volume 90% ethanol elutions of reuse are collected eluent, decompression recycling ethanol, concentrate, vacuum drying gets Herba Epimedii total flavones; (about general flavone content 55%)
Embodiments of the invention 15: the quality control method of preparation of the present invention adopts following method:
(1) finger printing of anti-viral pharmaceutical compositions test comprises based on the finger printing of Radix Scutellariae total flavones composition characteristics with based in the finger printing of Herba Epimedii total flavones composition characteristics one or more;
(2) baicalin, noroxylin, chrysin, icariin, icariside I, Herba Epimedii glycosides A, B, C, precious icariin I, II, the differential test method of all or part of composition in VI, the Quercetin;
(3) baicalin, noroxylin, chrysin, icariin, icariside I, Herba Epimedii glycosides A, B, C, precious icariin I, II, the content test method of all or part of composition in VI, the Quercetin; No matter effective site among the above embodiment can be alcohol extract, water extract, water extract-alcohol precipitation extract, semi-bionic extraction thing or supercritical extract with commercially available or make by the inventive method.
Claims (15)
1, a kind of antivirus compound formulation is characterized in that: calculate according to percentage by weight, it is to be made by Radix Scutellariae total flavones 1～99% and Herba Epimedii total flavones 99～1% and suitable adjuvant.
2, according to the described a kind of antivirus compound formulation of claim 1, it is characterized in that: calculate according to percentage by weight, it is to be made by Radix Scutellariae total flavones 20～80% and Herba Epimedii total flavones 80～20% and suitable adjuvant.
3, according to claim 1 or 2 described a kind of antivirus compound formulations, it is characterized in that: calculate according to percentage by weight, it is to be made by Radix Scutellariae total flavones 60～40%, Herba Epimedii total flavones 40～60% and suitable adjuvant.
4, according to any described a kind of antivirus compound formulation of claim 1～3, it is characterized in that: the Radix Scutellariae total flavones in the described prescription can be the highly finished product of Radix Scutellariae alcohol extract, Radix Scutellariae water extract, Radix Scutellariae water extract-alcohol precipitation extract, Radix Scutellariae semi-bionic extraction thing, Radix Scutellariae supercritical extract or above each extract; Herba Epimedii total flavones can be the highly finished product of Herba Epimedii alcohol extract, Herba Epimedii water extract, Herba Epimedii water extract-alcohol precipitation extract, Herba Epimedii semi-bionic extraction thing, Herba Epimedii supercritical extract or above each extract.
5, according to any described a kind of antivirus compound formulation of claim 1～4, it is characterized in that: described preparation be directly used in the injection of drug administration by injection, directly for the venous transfusion of intravenous drip, need to be used for after the dilution all receptible dosage forms on the concentrated solution for injection of intravenous drip and the injectable sterile powder that makes with freeze-drying or spray drying method and aseptic block and the pharmaceuticss such as tablet, capsule, granule, drop pill, pill, soft capsule, oral liquid, oral cavity disintegration tablet and dispersible tablet.
6, according to the described a kind of antivirus compound formulation of claim 5, it is characterized in that: described preparation can be various injections, drop pill, sublingual lozenge, oral cavity disintegration tablet, dispersible tablet, soft capsule, capsule, ordinary tablet.
7, according to claim 5,6 described a kind of antivirus compound formulations, it is characterized in that: described preparation can make on the basis that in Radix Scutellariae total flavones, the Herba Epimedii total flavones one or both is prepared into liposome or pro-liposome.
8, according to any described a kind of antivirus compound formulation in the claim 1～7, it is characterized in that: contain flavones ingredient in the preparation, wherein 70% of the total solid of the total flavones in the injection after greater than deduction adjuvant amount and water quantities in the preparation, 50% of the total solid of the total flavones in the oral formulations after greater than deduction adjuvant amount and water quantities in the preparation.
9,, it is characterized in that described drug effective region is commercially available or adopts following method to prepare as any described a kind of antivirus compound formulation in the claim 1～8:
A, Radix Scutellariae total flavones effective site are preparations like this: get radix scutellariae medicinal materials, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Radix Scutellariae total flavones crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Radix Scutellariae total flavones effective site;
B, Herba Epimedii total flavones effective site are preparations like this: get epimedium herb, adding entry or alcoholic solution after the pulverizing extracts, merge extractive liquid,, filter, concentrate the Herba Epimedii total flavones crude extract, adopt in ethanol precipitation, column chromatography, extraction, the flocculent precipitation one or more to unite on this basis to use carry out suitably refining, Herba Epimedii total flavones effective site.
10, preparation method according to any described a kind of antivirus compound formulation in the claim 1～7, it is characterized in that: the Injectable sterile block in the described preparation prepares like this: get Radix Scutellariae total flavones, Herba Epimedii total flavones, add 1800ml water for injection, press medicine and added mannitol than 1: 2.2 with supplementary product consumption, with saturated sodium hydroxide solution adjust pH to 6.5～7.5, add the injection water to 2000ml, mixing, the needle-use activated carbon of adding 0.4%, boiled 40 minutes, coarse filtration, reuse 0.45 μ m and 0.22 μ m microporous filter membrane filter, the filtrate packing, every bottle of 2.0ml, lyophilization, the equilibration time when the balance solidification point of phase I is 0 ℃ is 3.5 hours, i.e. the time of shelf temperature and product temperature basically identical; The second stage solidification point is from 0 ℃ during to minimum eutectic temperature-18 ℃, and shelf temperature and product temperature equilibration time are 2 hours; Phase III continues to be cooled to-35 ℃, needs 3.5 hours approximately, keeps this temperature 2.5 hours, freeze the jail fully until product, promptly begin evacuation, enter drying program, evacuation under-40 ℃ of constant temperature slowly heats up 3～5 ℃/h, to the lowest total of the melting point temperature, the time is about 8 hours, after sublimation drying is finished, continuation is under the low pressure condition, and it is dry to remove residual moisture to heat up, and the time is about 4～6 hours, kept more than 35 ℃ dry 4 hours, gland, promptly.
11, according to the preparation method of any described antivirus compound formulation in the claim 1～7, it is characterized in that: described sublingual lozenge is such preparation: the extract of getting Radix Scutellariae total flavones, Herba Epimedii total flavones mixes, add 5% lactose, 15% mannitol, 25% magnesium stearate, cross 30 mesh sieves, add an amount of Pulvis Talci, micropowder silica gel, evenly mixed, tabletting promptly gets sublingual lozenge.
12, according to any described antivirus compound formulation in the claim 1～7,9 or 10, it is characterized in that: adjuvant can be one or more in lactose, galactose, mannitol, corn starch, polyvinylpyrrolidone K30, citric acid, sodium citrate, magnesium stearate, pigment, acetoacetate derivative, sweeting agent, spice, glycine, glucose, sodium chloride, dextran, glycerol, ethanol, propylene glycol, Polyethylene Glycol, sorbitol, tween, HP-, the poloxamer.
13, according to the preparation method of the described antivirus compound formulation of claim 7, it is characterized in that: the pro-liposome in the described preparation prepares like this: get Radix Scutellariae total flavones, Herba Epimedii total flavones, add the phosphate buffer dissolving, add in the fused solution of fabaceous lecithin, cholesterol and 18-amine. mixing, stir supersound process, freezing, the dry powder that obtains sieves, promptly.
14, as the application of any described antivirus compound formulation in the claim 1～11, it is characterized in that: described method of quality control comprise in the following method partly or entirely:
(1) finger printing of anti-viral pharmaceutical compositions test comprises based on the finger printing of Radix Scutellariae total flavones composition characteristics with based in the finger printing of Herba Epimedii total flavones composition characteristics one or more;
(2) baicalin, noroxylin, chrysin, icariin, icariside I, Herba Epimedii glycosides A, B, C, precious icariin I, II, the differential test method of all or part of composition in VI, the Quercetin;
(3) baicalin, noroxylin, chrysin, icariin, icariside I, Herba Epimedii glycosides A, B, C, precious icariin I, II, the content test method of all or part of composition in VI, Quercetin, the total flavones.
15, as the application of any described antivirus compound formulation in the claim 1～3, it is characterized in that: described preparation is used to prepare the medicine of diseases such as treatment pneumonia, respiratory tract infection, influenza, bird flu, SARS, asthma, human body immunity improving power.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510123994 CN1969871A (en) | 2005-11-24 | 2005-11-24 | Antivirus compound formulation, preparation process, quality control method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510123994 CN1969871A (en) | 2005-11-24 | 2005-11-24 | Antivirus compound formulation, preparation process, quality control method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1969871A true CN1969871A (en) | 2007-05-30 |
Family
ID=38111019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510123994 Pending CN1969871A (en) | 2005-11-24 | 2005-11-24 | Antivirus compound formulation, preparation process, quality control method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1969871A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104706683A (en) * | 2013-12-12 | 2015-06-17 | 遵义医学院附属医院 | Rhizoma drynariae general flavone-phosphatide complex, preparation method and detection method thereof |
| CN105193751A (en) * | 2015-10-16 | 2015-12-30 | 孙民富 | Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials |
| CN111728979A (en) * | 2020-08-13 | 2020-10-02 | 华中科技大学协和深圳医院 | Use of Baohuogan I for anti-Staphylococcus aureus biofilm infection |
| CN111759880A (en) * | 2020-06-09 | 2020-10-13 | 广东金骏康生物技术有限公司 | Epimedium herb extract and application thereof in preventing or treating coronavirus |
-
2005
- 2005-11-24 CN CN 200510123994 patent/CN1969871A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104706683A (en) * | 2013-12-12 | 2015-06-17 | 遵义医学院附属医院 | Rhizoma drynariae general flavone-phosphatide complex, preparation method and detection method thereof |
| CN104706683B (en) * | 2013-12-12 | 2018-04-20 | 遵义医学院附属医院 | Process of Total Flavonoids in Drynaria Fortunei phospholipid complexes and preparation method thereof and its detection method |
| CN105193751A (en) * | 2015-10-16 | 2015-12-30 | 孙民富 | Oral sublingual tablet formula and method for preparing oral sublingual tablet by using insulin lipidosome, insulin microsphere (capsule), and insulin nanoparticle (capsule) as raw materials |
| CN111759880A (en) * | 2020-06-09 | 2020-10-13 | 广东金骏康生物技术有限公司 | Epimedium herb extract and application thereof in preventing or treating coronavirus |
| CN111728979A (en) * | 2020-08-13 | 2020-10-02 | 华中科技大学协和深圳医院 | Use of Baohuogan I for anti-Staphylococcus aureus biofilm infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6091651B2 (en) | Pharmaceutical composition for treating headache and method for preparing the same | |
| CA2754064C (en) | Plant extract compositions for the treatment of influenza and inflammation | |
| CN102430090A (en) | Traditional Tibetan medicine Ruyizhenbao composite preparation and preparation method thereof | |
| CN101152324A (en) | Method for producing Yujin composition and medicament containing the same | |
| CN101011452A (en) | Plant extract with hypotensive effect and its preparing process and use | |
| CN1969997A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN1970000A (en) | Antivirus Chinese medicinal formulation, preparation process, quality control method and application thereof | |
| CN1969871A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN1970032B (en) | Chinese medicine containing honeysuckle flower and weeping forsythia for treating cold | |
| CN100479825C (en) | Application of gentiopicroside in preparation of antiviral medicament | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN1969952A (en) | Antivirus Chinese medicinal formulation, preparation process, quality control method and use thereof | |
| CN1969870A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN101088533A (en) | Antiviral Chinese medicine prepn and its prepn process, quality control method and application | |
| CN1969998A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN1969999A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN1969869A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN101974012B (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
| CN102351874B (en) | New erigeroster compound with medicinal activity | |
| CN101816706B (en) | Chinese traditional medicament valid target composition for treating viral respiratory infection diseases | |
| CN101966196A (en) | Formula of catalpol-puerarin injection and powder and preparation method | |
| CN110302301A (en) | A traditional Chinese medicine composition and its application in the treatment of steroid-induced necrosis of the femoral head | |
| CN110302166A (en) | A kind of swap buffers tablet and preparation method thereof | |
| CN101974010B (en) | New compound erigeron breviscapus acid with officinal activity | |
| JP5876856B2 (en) | Use of an effective fraction of alkaloids derived from mulberry branches to prepare hypoglycemic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |